ANIMA - ItalyNCT07543419
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria revised
- Trial sites expanded: 16 → 22 locations
- Secondary endpoints: details revised at 10 of 34 entries
- Minor Trial sites expanded: 11 → 16 locationsv3
- Minor Trial sites expanded: 8 → 11 locationsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55) during the observational period.
Timeframe: Baseline,6 months and 1 and 1,5 years after initiation of secukinumab
Secondary (34)
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55) stratified by dosing
Proportion of patients achieving 75% reduction in IHS4 (IHS4-75) and 100% reduction in IHS4 (IHS4-100)
Proportion of patients achieving 50% reduction in HiSCR (HiSCR-50) and 75% reduction in HiSCR (HiSCR-75)
Number, type, and localization of HS lesions
Change of total abscess and inflammatory nodule count
Show 29 moreShow less
Proportion of patients receiving up-titration
Proportion of patients receiving down-titration
Time to up-titration and down-titration
Proportion of patients switching from q4w to q2w treatment
Proportion of patients who receive more than one up- and/or down-titration
Demographics of adult patients with moderate or severe HS
Proportion of patients achieving a 5-point reduction of Dermatology life quality index (DLQI) score.
Change in DLQI score from baseline
Clinical characteristics of adult patients with moderate to severe HS
Proportion of patients with new draining tunnel
Number of areas affected and proportion of patients with additional area involvement
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Time of initiation of concomitant medications
Duration of treatment with concomitant medications
Proportion of patients undergoing tapering of concomitant medications
Number and type of surgical interventions
Reason for surgical intervention
Duration of discontinuation/pause of secukinumab treatment before surgery
Duration of discontinuation/pause of secukinumab treatment after surgery
Reduction in the number of surgical procedures
Identification of potential predictors using multivariable analysis
Descriptive statistics of pain
Proportion of patients achieving a 30% reduction of Pain Numerical Rating scale (NRS30)
Number of patients with secukinumab AEs in routine clinical practice
Hospital Anxiety and Depression Scale [HADS] score
Healthcare Resource Utilization of adult patients with HS
Costs of HS covered by the Italian National Health System
Direct costs not covered by the SSN and indirect costs of HS
Analysis on HS-related surgeries per patient and related direct costs covered by SSN
Sites
22 sites in 1 country